Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
90.60
+3.97 (4.58%)
At close: Jun 26, 2026, 4:00 PM EDT
90.53
-0.07 (-0.08%)
After-hours: Jun 26, 2026, 7:41 PM EDT
Oruka Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Oruka Therapeutics stock have an average target of 138.82, with a low estimate of 45 and a high estimate of 200. The average target predicts an increase of 53.22% from the current stock price of 90.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Oruka Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $120 | Buy | Reiterates | $120 | +32.45% | Jun 23, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $180 | Buy | Maintains | $180 | +98.68% | Jun 2, 2026 |
| UBS | UBS | Buy Reiterates $100 | Buy | Reiterates | $100 | +10.38% | Jun 2, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 2, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $125 | Buy | Maintains | $125 | +37.97% | May 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.04
from -1.85
EPS Next Year
-2.46
from -2.04
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.69 | -1.37 | |
| Avg | -2.04 | -2.46 | |
| Low | -2.77 | -4.12 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.